KR20220139445A - 암 치료를 위한 병용 요법 - Google Patents

암 치료를 위한 병용 요법 Download PDF

Info

Publication number
KR20220139445A
KR20220139445A KR1020227034306A KR20227034306A KR20220139445A KR 20220139445 A KR20220139445 A KR 20220139445A KR 1020227034306 A KR1020227034306 A KR 1020227034306A KR 20227034306 A KR20227034306 A KR 20227034306A KR 20220139445 A KR20220139445 A KR 20220139445A
Authority
KR
South Korea
Prior art keywords
vtp
bchl
treatment
pdt
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020227034306A
Other languages
English (en)
Korean (ko)
Inventor
아비그도르 셸츠
요람 살로몬
리락흐 아게미
레이첼 하므리
디나 프레이즈
광희 김
조나단 콜먼
Original Assignee
예다 리서치 앤드 디벨럽먼트 캄파니 리미티드
메모리얼 슬로안 케터링 캔서 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드, 메모리얼 슬로안 케터링 캔서 센터 filed Critical 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드
Publication of KR20220139445A publication Critical patent/KR20220139445A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227034306A 2016-04-10 2017-04-10 암 치료를 위한 병용 요법 Abandoned KR20220139445A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662320549P 2016-04-10 2016-04-10
US62/320,549 2016-04-10
PCT/IL2017/050440 WO2017179053A1 (en) 2016-04-10 2017-04-10 Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative
KR1020187032029A KR20190008206A (ko) 2016-04-10 2017-04-10 암 치료를 위한 병용요법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187032029A Division KR20190008206A (ko) 2016-04-10 2017-04-10 암 치료를 위한 병용요법

Publications (1)

Publication Number Publication Date
KR20220139445A true KR20220139445A (ko) 2022-10-14

Family

ID=58794130

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227034306A Abandoned KR20220139445A (ko) 2016-04-10 2017-04-10 암 치료를 위한 병용 요법
KR1020187032029A Abandoned KR20190008206A (ko) 2016-04-10 2017-04-10 암 치료를 위한 병용요법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187032029A Abandoned KR20190008206A (ko) 2016-04-10 2017-04-10 암 치료를 위한 병용요법

Country Status (14)

Country Link
US (2) US11278555B2 (https=)
EP (1) EP3442582A1 (https=)
JP (2) JP2019510807A (https=)
KR (2) KR20220139445A (https=)
CN (2) CN109862918A (https=)
AU (2) AU2017250732B2 (https=)
BR (1) BR112018070847A2 (https=)
CA (1) CA3020067A1 (https=)
IL (1) IL262191B2 (https=)
MX (2) MX390751B (https=)
RU (2) RU2021110230A (https=)
SG (1) SG11201808849TA (https=)
WO (1) WO2017179053A1 (https=)
ZA (1) ZA201807187B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10107240B2 (en) 2014-04-04 2018-10-23 Dayco Ip Holdings, Llc Check valves and Venturi devices having the same
JP6609626B2 (ja) 2014-05-30 2019-11-20 デイコ アイピー ホールディングス，エルエルシー エジェクタ、空圧式制御バルブ及び選択的なアスピレータを有する真空発生システム
EP3723785A1 (en) * 2017-12-17 2020-10-21 Yeda Research and Development Co. Ltd Cop9 signalosome (csn) complex modulators and uses thereof
KR20220100546A (ko) * 2021-01-08 2022-07-15 가톨릭대학교 산학협력단 암세포의 항암 면역치료를 위한 항체-폴리에틸렌글리콜-광감각제 접합체

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1137411B1 (en) 1998-12-09 2006-12-06 YEDA RESEARCH AND DEVELOPMENT Co. LTD. Palladium-substituted bacteriochlorophyll derivatives and use thereof
IL133253A0 (en) * 1999-12-01 2001-04-30 Yeda Res & Dev Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
IL152900A0 (en) * 2002-11-17 2003-06-24 Yeda Res & Dev Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses
RU2450018C2 (ru) * 2006-08-23 2012-05-10 Йеда Рисерч Энд Диверлопмент Ко. Лтд Конъюгаты rgd-пептидов и фотосенсибилизаторов порфирина или (бактерио)хлорофилла и их применение
ES2627377T3 (es) 2008-10-23 2017-07-27 Steba Biotech S.A. Peptidomiméticos que contienen RGD y sus usos
AU2012212323A1 (en) * 2011-02-01 2013-09-12 The Board Of Trustees Of The University Of Illinois HDAC inhibitors and therapeutic methods using the same
TWI442945B (zh) * 2011-05-18 2014-07-01 Univ Nat Taiwan 雙效微脂體用於治療的方法
WO2014141289A1 (en) 2013-03-12 2014-09-18 Amrita Vishwa Vidyapeetham University Photo - chemo composition on the basis of microcapsules with a core -shell structure

Also Published As

Publication number Publication date
CA3020067A1 (en) 2017-10-19
IL262191B2 (en) 2025-01-01
AU2023200591A1 (en) 2023-03-09
JP2019510807A (ja) 2019-04-18
CN118304400A (zh) 2024-07-09
SG11201808849TA (en) 2018-11-29
RU2018139523A3 (https=) 2020-07-07
IL262191B1 (en) 2024-09-01
JP2022031823A (ja) 2022-02-22
CN109862918A (zh) 2019-06-07
BR112018070847A2 (pt) 2019-02-05
US11278555B2 (en) 2022-03-22
IL262191A (en) 2018-11-29
WO2017179053A1 (en) 2017-10-19
AU2017250732A1 (en) 2018-11-15
EP3442582A1 (en) 2019-02-20
US20220202838A1 (en) 2022-06-30
AU2017250732B2 (en) 2022-11-10
MX390751B (es) 2025-03-21
RU2747258C2 (ru) 2021-04-29
MX2018012392A (es) 2019-08-21
US20190125769A1 (en) 2019-05-02
RU2018139523A (ru) 2020-05-15
ZA201807187B (en) 2020-01-29
RU2021110230A (ru) 2021-05-26
KR20190008206A (ko) 2019-01-23
MX2022003190A (es) 2022-04-11

Similar Documents

Publication Publication Date Title
US20220202838A1 (en) Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative
Zhang et al. Abscopal effects with hypofractionated schedules extending into the effector phase of the tumor-specific T-cell response
Zhu et al. Tumor‐targeted nano‐adjuvants to synergize photomediated immunotherapy enhanced antitumor immunity
KR102535283B1 (ko) 암의 치료를 위한 조합 요법
Curtin et al. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials
EP2234642B1 (en) Method of increasing immunological effect
US20150344577A1 (en) Agents for treating tumors, use and method thereof
Caisová et al. Effective cancer immunotherapy based on combination of TLR agonists with stimulation of phagocytosis
KR20190096936A (ko) 암 치료를 위하여 tlr9 작용제를 사용한 면역 조정
US20140322242A1 (en) Materials and methods for the prevention and treatment of cancer
Milling et al. Neoadjuvant STING activation, extended half-life IL2, and checkpoint blockade promote metastasis clearance via sustained NK-cell activation
US20220313822A1 (en) Near-infrared (nir) photoimmunotherapy (pit) for the treatment of cancers using anti-cd25 antibody-phthalocyanine dye conjugate and anti-pd1 antibody
US20200377596A1 (en) Dosing of bispecific t cell engager
KR20080091427A (ko) 동시 화학요법 및 면역요법
Donahue et al. A pan inhibitor of DASH family enzymes induces immunogenic modulation and sensitizes murine and human carcinoma cells to antigen-specific cytotoxic T lymphocyte killing: implications for combination therapy with cancer vaccines
Crespo-Garcia et al. Unleashing anti-tumour immunity: dietary restriction and exercise interventions adjunct to chemotherapy for cancer patients.
US20230270861A1 (en) Inhibitors of the Artemin Pathway for Treatment of Cancer
US20220296712A1 (en) Methods for treatment using phthalocyanine dye-targeting molecule conjugates
JP2023505303A (ja) 癌治療におけるｉｌ－１５及びｃｄ４０アゴニストの組合せ免疫療法
IL269769A (en) Compounds, composition and uses thereof for treating cancer
Chen et al. A rapid ex vivo co-culture of memory-like NK and activated T cells enhances anti-tumor response in gastric cancer.
Lobo Immunological Effects of Photodynamic Therapy
Zhang et al. In situ therapeutic vaccines for leukemia by chemo-nanoadjuvant therapy
WO2023203561A1 (en) Apoptotic cell - check point inhibitor combination therapy
Wang et al. Reprogramming Chemoimmunotherapy via Biomimetic Cell Membrane-Clay Platform to Amplify Prime–Boost Antitumor Immunity

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PC1904 Unpaid initial registration fee

St.27 status event code: N-2-6-B10-B12-nap-PC1904

St.27 status event code: A-2-2-U10-U14-oth-PC1904